Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Anthilia Capital Partners provides RT&L EUR 10 million acquisition loan

Anthilia Capital Partners provides RT&L EUR 10 million acquisition loan

ReutersReuters2026/08/04 14:19
  • RT&L entered a new EUR 10 million financing line from Anthilia Capital Partners, funded via Anthilia BIT V and Anthilia ELTIF Synthesis.
  • Proceeds will fund the acquisition of the LandS group, supporting RT&L’s external growth strategy.
  • The facility has a 6.5-year tenor, including an 18-month pre-amortization period.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RT&L S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20351_170678_2026_oneinfo.pdf), on August 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas